Company Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.
The company was incorporated in 2019 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jul 19, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Fred Aslan |
Contact Details
Address: 5505 Morehouse Drive, Suite 100 San Diego, California 92121 United States | |
| Phone | (858) 267-4467 |
| Website | artivabio.com |
Stock Details
| Ticker Symbol | ARTV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001817241 |
| Employer ID | 86-3614316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Fred Aslan M.D. | President, Chief Executive Officer and Director |
| Dr. Peter Flynn Ph.D. | Co-Founder and Strategic Advisor |
| Jennifer Kinsbruner Bush Esq., J.D. | Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer |
| Christopher P. Horan | Chief Technical Operations Officer |
| Neha Krishnamohan | Chief Financial Officer and Executive Vice President of Corporate Development |
| Dr. Thorsten Graef M.D., Ph.D. | Chief Medical Officer |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research and Early Development |
| Javier Coindreau M.D. | Senior Vice President of Medical Affairs |
| Dr. David Moriarty Ph.D. | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | 8-K | Current Report |
| Sep 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 29, 2024 | 10-Q | Quarterly Report |
| Aug 29, 2024 | 8-K | Current Report |
| Aug 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 29, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jul 29, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jul 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |